These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18606668)

  • 1. B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathway.
    Su Y; Carey G; Maric M; Scott DW
    J Immunol; 2008 Jul; 181(2):1153-60. PubMed ID: 18606668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells.
    El-Amine M; Melo M; Kang Y; Nguyen H; Qian J; Scott DW
    J Immunol; 2000 Nov; 165(10):5631-6. PubMed ID: 11067919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment.
    Dani A; Chaudhry A; Mukherjee P; Rajagopal D; Bhatia S; George A; Bal V; Rath S; Mayor S
    J Cell Sci; 2004 Aug; 117(Pt 18):4219-30. PubMed ID: 15316082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing.
    Li P; Gregg JL; Wang N; Zhou D; O'Donnell P; Blum JS; Crotzer VL
    Immunol Rev; 2005 Oct; 207():206-17. PubMed ID: 16181338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment.
    el-Amine M; Hinshaw JA; Scott DW
    Int Immunol; 2002 Jul; 14(7):761-6. PubMed ID: 12096035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.
    Crotzer VL; Glosson N; Zhou D; Nishino I; Blum JS
    Immunology; 2010 Nov; 131(3):318-30. PubMed ID: 20518820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
    Brocke P; Armandola E; Garbi N; Hämmerling GJ
    Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation.
    Ashour HM; Niederkorn JY
    J Immunol; 2006 May; 176(10):5950-7. PubMed ID: 16670303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early endosomes are required for major histocompatiblity complex class II transport to peptide-loading compartments.
    Brachet V; Péhau-Arnaudet G; Desaymard C; Raposo G; Amigorena S
    Mol Biol Cell; 1999 Sep; 10(9):2891-904. PubMed ID: 10473634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GILT in Thymic Epithelial Cells Facilitates Central CD4 T Cell Tolerance to a Tissue-Restricted, Melanoma-Associated Self-Antigen.
    Rausch MP; Meador LR; Metzger TC; Li H; Qiu S; Anderson MS; Hastings KT
    J Immunol; 2020 Jun; 204(11):2877-2886. PubMed ID: 32269095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transport of peptide-MHC class II complexes in developing dendritic cells.
    Turley SJ; Inaba K; Garrett WS; Ebersold M; Unternaehrer J; Steinman RM; Mellman I
    Science; 2000 Apr; 288(5465):522-7. PubMed ID: 10775112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
    Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
    J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
    Dissanayake SK; Tuera N; Ostrand-Rosenberg S
    J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.
    Becker HJ; Kondo E; Shimabukuro-Vornhagen A; Theurich S; von Bergwelt-Baildon MS
    Eur J Haematol; 2016 Aug; 97(2):166-74. PubMed ID: 26561366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for immunologic tolerance: using bone marrow-derived cells to treat autoimmunity and hemophilia.
    Scott DW
    Curr Stem Cell Res Ther; 2011 Mar; 6(1):38-43. PubMed ID: 20955157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
    Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
    J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments.
    Mahnke K; Guo M; Lee S; Sepulveda H; Swain SL; Nussenzweig M; Steinman RM
    J Cell Biol; 2000 Oct; 151(3):673-84. PubMed ID: 11062267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity.
    Phipps-Yonas H; Semik V; Hastings KT
    Eur J Immunol; 2013 Jan; 43(1):65-74. PubMed ID: 23012103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis.
    Mukherjee P; Dani A; Bhatia S; Singh N; Rudensky AY; George A; Bal V; Mayor S; Rath S
    J Immunol; 2001 Sep; 167(5):2632-41. PubMed ID: 11509605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.
    Buetow KH; Meador LR; Menon H; Lu YK; Brill J; Cui H; Roe DJ; DiCaudo DJ; Hastings KT
    J Immunol; 2019 Nov; 203(10):2577-2587. PubMed ID: 31591149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.